Norbert VEY
MD
-
Director of Clinical Research at 'Institut Paoli Calmettes" | Coordinator of the Clinical and Translational Program for Leukemia and Myeloid Hemopathies at t"Institut Paoli Calmettes" | Coordinator of the Labelled Center for Early Phase Trials (CLIP²), Professor of Hematology at Aix-Marseille University
AMU, IPC
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Have a look on our testimonies
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
Laurent GREILLIER
AP-HM, AMU
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
Christian CHABANNON
AMU, IPC, AP-HM, Inserm
Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective
Nassima CHOUAKI BENMANSOUR
AP-HM
your commitment to MI